RxDoctor Payments Data

Scott Fudemberg, MD

Ophthalmology · Rehoboth Beach, DENPI 1568510675

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,125 of the $4,608 with a category attached, or 67.8%. 15 manufacturers reported payments, led by AbbVie at 57.4% of the total. Reporting peaked in 2020 at $2,358 and has fallen 73.6% since, to $623 in 2025.

$4,608in general payments, 2019–2025

Across 28 payments — averaging $164.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Aerie Pharmaceuticals, Inc.$1K
  • Carl Zeiss Meditec USA, Inc.$317
  • Astellas Pharma US Inc$132
  • Regeneron$124
  • Carl Zeiss Meditec AG$39
  • plus $194 from 9 others

What the payments were for

  • Consulting fees$3,12568%
  • Speaking & faculty fees$1002%
  • Food & beverage$1,28728%
  • Education$401%
  • Gifts$561%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,608 in reported general payments places this provider in the 80th percentile of 49 ophthalmology providers in Delaware.

See all ophthalmology providers in Delaware

Medicare billing

Part B allowed, 2024
$557,881
Medicare patients
1,119
Services billed
5,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate439$234,522
LumiganBimatoprost189$125,033
Brimonidine Tartrate1,074$33,787
SimbrinzaBrinzolamide/Brimonidine Tart107$29,092
Brinzolamide128$28,485
Latanoprost2,420$27,724
Prednisolone Acetate519$27,281
VyzultaLatanoprostene Bunod44$25,712
RocklatanNetarsudil Mesylat/Latanoprost50$23,443
CombiganBrimonidine Tartrate/Timolol40$20,251
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,147$20,077
Dorzolamide Hcl897$19,169
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol92$17,711
Dorzolamide-TimololDorzolamide/Timolol/Pf83$15,939
Alphagan PBrimonidine Tartrate49$15,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$1,159$257,964489 claims
AbbVieLumigan, Combigan, Alphagan P$2,643$161,174278 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$21$3,70213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 49 ophthalmology providers in Delaware.

Other ophthalmology in Rehoboth Beach

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →